Descriptive Pharmacoepidemiological Study of Patients Treated With Iressa (EPIDAURE)

AstraZeneca

Status: Completed

Conditions: Lung Cancer

Study type: Observational

Funder types: Industry

Identifiers

NCT01448187

NIS-OFR-IRE-2011/1

Details and patient eligibility

About

The aim of the study is to describe the characteristics of patients treated with Iressa (particularly age, gender, phenotype, histology and stage of disease, line of treatment and previous treatments, smoking history, conditions of initiation of treatment (presence of an EGFR-activating mutation) and to evaluate the impact of treatment on the health of the population concerned in terms of morbidity and mortality (clinical benefit, safety,...) and quality of life

Full description

Descriptive pharmacoepidemiological study of patients treated with Iressa

Enrollment: 361 patients

Sex: All

Ages: Under 130 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients treated with Iressa

Exclusion criteria

• Patient included in a therapeutic trial comprising protocol use of Iressa
• Patient included in a therapeutic trial (Huriet-Serusclat Act)
• Patient refusing to participate in the study